Eric Quéméneur
Chief Tech/Sci/R&D Officer at TRANSGENE
Profile
Eric Quéméneur is currently the Director & EVP-Research & Development at ElsaLys Biotech SAS and the Chief Scientific Officer & Executive VP at Transgene SA. Previously, he worked as the Director-Research Programs at Comité de l’énergie Atomique from 1990 to 2014.
Dr. Quéméneur holds a doctorate degree from Université Claude Bernard Lyon 1 and an undergraduate degree from Institut National des Sciences Appliquées de Lyon, which he obtained in 1986.
Eric Quéméneur active positions
Companies | Position | Start |
---|---|---|
TRANSGENE | Chief Tech/Sci/R&D Officer | 2014-08-31 |
ELSALYS BIOTECH | Chief Tech/Sci/R&D Officer | - |
Former positions of Eric Quéméneur
Companies | Position | End |
---|---|---|
Comité de l’énergie Atomique | Corporate Officer/Principal | 2014-08-31 |
Training of Eric Quéméneur
Université Claude Bernard Lyon 1 | Doctorate Degree |
Institut National des Sciences Appliquées de Lyon | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
TRANSGENE | Health Technology |
Private companies | 2 |
---|---|
ElsaLys Biotech SAS
ElsaLys Biotech SAS Pharmaceuticals: MajorHealth Technology ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France. | Health Technology |
Comité de l’énergie Atomique | Government |
- Stock Market
- Insiders
- Eric Quéméneur